Protonix settlement unlikely to eclipse Sun's business plans
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries is unlikely to scale down its growth projections for 2014 or rein in plans to expand via acquisitions as a result of the $550 million settlement over the patent dispute concerning its generic version of Pfizer's gastroesophageal reflux disease treatment, Protonix (pantoprazole).